Brussels, 22/07/2014 (Agence Europe) - On Tuesday 22 July, the European Commission gave the go-ahead to the creation of a joint venture by Allergopharma GmbH & Co. KG of Germany, Stallergenes S.A. of France and Laboratorios LETI, S.L. Unipersonal of Spain. Allergopharma is active in the fields of allergen immunotherapy, allergy diagnostics and allergy prevention in 25 countries, but mostly in Germany; Stallergenes is a global healthcare company specialised in the diagnosis and treatment of...